Patterns of care and clinical outcomes of first-line trastuzumab-based therapy in HER2-positive metastatic breast cancer patients relapsing after (Neo)adjuvant trastuzumab: An Italian multicenter retrospective cohort study

Matteo Lambertini, Arlindo R. Ferreira, Francesca Poggio, Fabio Puglisi, Antonio Bernardo, Filippo Montemurro, Elena Poletto, Emma Pozzi, Valentina Rossi, Emanuela Risi, Antonella Lai, Elisa Zanardi, Valentina Sini, Serena Ziliani, Gabriele Minuti, Silvia Mura, Donatella Grasso, Andrea Fontana, Lucia del Mastro

Research output: Contribution to journalArticlepeer-review

Abstract

Background. We evaluated the patterns of care and clinical outcomes of metastatic breast cancer patients treated with first-line trastuzumab-based therapy after previous (neo)adjuvant trastuzumab. Materials and Methods. A total of 416 consecutive, HER2-positive metastatic breast cancer patients who had received first-line trastuzumab-based therapy were identified at 14 Italian centers. A total of 113 patients had presented with de novo stage IV disease and were analyzed separately. Dichotomous clinical outcomes were analyzed using logistic regression and time-to-event outcomes using Cox proportional hazards models. Results. In the 202 trastuzumab-naive patients and 101 patients with previous trastuzumab exposure, we observed the following outcomes, respectively: overall response rate, 69.9% versus 61.3% (adjusted odds ratio [OR], 0.62; p =.131), clinical benefit rate, 79.1% versus 72.5% (adjusted OR, 0.73; p =.370), median progression-free survival (PFS), 16.1 months versus 12.0 months (adjusted hazards ratio [HR], 1.33; p =.045), and median overall survival (OS), 52.2 months versus 48.2 months (adjusted HR, 1.18; p =.404). Patients with a trastuzumab-free interval (TFI)

Original languageEnglish
Pages (from-to)880-889
Number of pages10
JournalThe oncologist
Volume20
Issue number8
DOIs
Publication statusPublished - 2015

Keywords

  • HER2+
  • Metastatic breast cancer
  • Neoadjuvant/adjuvant trastuzumab
  • Retreatment
  • Trastuzumab-free interval

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint

Dive into the research topics of 'Patterns of care and clinical outcomes of first-line trastuzumab-based therapy in HER2-positive metastatic breast cancer patients relapsing after (Neo)adjuvant trastuzumab: An Italian multicenter retrospective cohort study'. Together they form a unique fingerprint.

Cite this